Business Context and Reporting Period
DBV Technologies S.A., a biopharmaceutical company developing epicutaneous immunotherapy (EPIT) for food allergies and immune diseases, filed this Form 6-K on July 27, 2018. The filing reports the company's cash position as of June 30, 2018.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (June 30, 2018) | €202.2 million |
| Cash and Cash Equivalents (Dec 31, 2017) | €137.9 million |
| Outstanding Shares (June 30, 2018) | 30,006,352 |
| Fully Diluted Shares (June 30, 2018) | 32,856,948 |
The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt.
Material Changes
- Cash and cash equivalents increased by €64.3 million, rising from €137.9 million as of December 31, 2017, to €202.2 million as of June 30, 2018.
Outlook, Risks, and Management Commentary
Management highlighted ongoing clinical trials for Viaskin Peanut and Viaskin Milk, as well as preclinical development for Viaskin Egg. The company is also pursuing a human proof-of-concept clinical study of Viaskin Milk for Eosinophilic Esophagitis and exploring applications in vaccines and other immune diseases. The filing does not contain specific forward-looking financial guidance, risk factors, or details on contingencies beyond the general description of clinical development stages.
Key Facts for Investor Verification
- Verify the source of the €64.3 million increase in cash (e.g., equity financing, grants, or other inflows) as the filing does not specify the cause.
- Confirm the status and timelines of the ongoing clinical trials for Viaskin Peanut and Viaskin Milk.
- Review the company's burn rate and runway given the lack of reported revenue in this filing.
- Check for any recent dilutive events affecting the fully diluted share count of 32,856,948.